The FDA approves alexinib as an adjuvant treatment for non-small cell lung cancer.

Published Date: 22 Apr 2024

Compared to chemotherapy, the ALK inhibitor lowered the risk of death or recurrence by 76%.

Read Full News

Latest News

EU Flags Shortage Of Schizophrenia Drug Injections Due to Manufacturing Issues

(This Aug 27 story has been republished, with no changes to text.)

Alzheimer's Blood Test Gets FDA Clearance

The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood ⁠test to help identify signs of Alzheimer's disease in people aged 55 and older with...

Less Seniors Taking Inappropriate Cognitive Meds

Older adults with cognitive disorders who use inappropriate medications linked to adverse cognitive effects are more likely to have poor mental health-related quality of life.

US Health Department Seeks Public Feedback on Vaccine Guidelines After Trump Order

The U.S. health department said on Friday it was seeking public feedback on federal vaccine recommendations, including how they ⁠are categorized and communicated, after...

Cognitive Therapy Boosts Brain Function in Schizophrenia

Structured cognitive remediation therapy helps boost brain activity, working memory, and quality of life and reduce severity of symptoms in patients with schizophrenia, a trial shows.

Did Breast Cancer Radiation Cause This Weird Lung Problem?

Especially peculiar since the patient had no risk factors

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Todays Updates

Milvexian Fails to Reduce CV Events After ACS

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

Atorvastatin Cuts Major CV Events by 30% in Older Adults in STAREE

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

Phase 3 Eplontersen Trial Results Disappoint

Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.

Latest News

(This Aug 27 story has been republished, with no changes to text.)

The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood ⁠test to help identify signs of Alzheimer's disease in people aged 55 and older with...

Older adults with cognitive disorders who use inappropriate medications linked to adverse cognitive effects are more likely to have poor mental health-related quality of life.

The U.S. health department said on Friday it was seeking public feedback on federal vaccine recommendations, including how they ⁠are categorized and communicated, after...

Structured cognitive remediation therapy helps boost brain activity, working memory, and quality of life and reduce severity of symptoms in patients with schizophrenia, a trial shows.

Especially peculiar since the patient had no risk factors

News All Time

Whole Foods Recall; RFK Jr.'s Voting Problem; Glass Particles in Biosimilar

Health news and commentary gathered by MedPage Today staff

Junk Food & Prostate Cancer; 'Office' Star's Stage IV Diagnosis; New Cancer Cluster?

News, features, and commentary about cancer-related issues

Genomic Newborn Screening Could Identify Childhood Cancer Predisposition

Testing could give doctors an early start on life-preserving cancer treatments

SBRT Misses the Mark in Prostate Cancer Trial

No improvement over intensity-modulated RT in urinary symptoms after 2 years, DFS after 3 years

What Caused This Young Man's Bladder Cancer

Occupational exposure, family history make tempting hypotheses

Dramatic Increase in Active Surveillance Use for Prostate Cancer

Soared past 90% in VA system for low-risk disease, to 61% for favorable intermediate-risk disease

Melanoma Patient on Immunotherapy Develops Severe Dermatitis

Clinicians faced with presumed dermatologic AEs urged to consider all differentials

Early Sugar Exposure and Cancer Risk; Melanoma Vaccine Win; 'Antifreeze' for CAR-T

News, features, and commentary about cancer-related issues

Hyponatremia Risk Varies Among Second-Gen Antipsychotics

Aripiprazole is associated with a lower risk for hyponatremia compared with olanzapine in patients treated with second-generation antipsychotics, a new cohort study shows.

Freeman’s Lobotomy to Deep Brain Stimulation: What Changed?

The history of lobotomy shows the risks for limited evidence and oversight, while modern approaches emphasize targeted treatment, informed consent, and rigorous evaluation.

Prolonged Screen Time Linked to Sleep Issues in Preschoolers

Preschool-aged children exposed to screens for extended daily periods face elevated prevalence of sleep disturbances.

US Mental Health Treatment Rates Rise But Gaps Persist

Treatment rates for US adults with psychiatric disorders are modestly higher than in previous decades, but only a third receive minimally adequate care, new research shows.

Cognitive Bias Modification App Fosters Alcohol Avoidance

An Australian-designed smartphone app uses personalized cognitive bias modification to help users reduce or avoid alcohol consumption.

Schizophrenia: Nighttime Light Tied to Metabolic Dysfunction

Higher vs lower nighttime light exposure is associated with increased risk for obesity, hypertension, and dyslipidemia in patients with schizophrenia, a study suggests.

Testicular Mass Serendipitously Found 12 Years After Prostate Cancer Dx

Consistently low PSA levels failed to signal metastasis

A Sinister Etiology for Shoulder Pain

Patient presented with what was assumed to be rotator cuff injury

Recommended News For You

Mindfulness-based interventions are advised by cancer organizations to treat patients' anxiety and depression.

The FDA approves alexinib as an adjuvant treatment for non-small cell lung cancer.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.

Acalabrutinib + Venetoclax Combo Earns FDA Nod for CLL

Quality of Life Similar With Proton Beam Therapy vs IMRT for Prostate Cancer

CAR-T cell therapy for cancer causes 'brain fog,' study shows

Recommended Articles For You

Obesity is a major risk factor for cancer 

Lymphomatoid Papulosis: What You Need to Know 

Immune Landscape Evolution in the Tumor Stromal Ecosystem 

Hemophilia Beyond Boundaries: Unconventional Therapies in Bleeding Disorder Care 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

EU Flags Shortage Of Schizophrenia Drug Injections Due to Manufacturing Issues

2.

Brain cancer: a Q&A session.

3.

Women are more susceptible to the stress caused by inflation.

4.

Use of social media during pregnancy may increase depression.

5.

A new theranostic drug targets different cancer types.

1.

Unlocking the Mysteries of the Axillary Vein: Exploring its Role in Human Anatomy

2.

How HLH is Revolutionizing Healthcare

3.

Unraveling the Mysteries of Burkitt Lymphoma: A New Hope for Treatment

4.

Landmark Medical Oncology Trials Redefining Early Breast Cancer Management

5.

Rehabilitation Through Prehabilitation Before Complex Cancer Surgery

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity

2.

Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations

3.

Should We Use DARA Up Front As First-Line Therapy in MM? - Part II

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

5.

From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot